Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Melanoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 38Nivolumab 24atezolizumab 10Ipilimumab 7Carboplatin 6avelumab 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Docetaxel 5Cyclophosphamide 5fludarabine 4cabozantinib 4Specimen Handling 4Pemetrexed 4regorafenib 3Interleukin-2 3Gemcitabine 3130-nm albumin-bound paclitaxel 3spartalizumab 2lenvatinib 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Immune Checkpoint Inhibitors 2Cisplatin 2Biopsy 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Heavy Ion Radiotherapy × Thoracic × Clear all
NCT05229614 2024-08-21

ICONIC

CNAO National Center of Oncological Hadrontherapy

Phase 2 Recruiting
27 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡